4/16
08:09 pm
acrv
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 [Yahoo! Finance]
High
Report
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 [Yahoo! Finance]
4/16
08:01 pm
acrv
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
High
Report
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
4/10
08:13 am
acrv
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan
High
Report
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan
4/10
08:00 am
acrv
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan
High
Report
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan
4/9
07:04 am
acrv
Acrivon Therapeutics Announces $130 Million Private Placement Financing [Yahoo! Finance]
Medium
Report
Acrivon Therapeutics Announces $130 Million Private Placement Financing [Yahoo! Finance]
4/9
07:00 am
acrv
Acrivon Therapeutics Announces $130 Million Private Placement Financing
High
Report
Acrivon Therapeutics Announces $130 Million Private Placement Financing
4/5
11:02 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target lowered by analysts at LADENBURG THALM/SH SH from $18.00 to $14.00. They now have a "buy" rating on the stock.
Neutral
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target lowered by analysts at LADENBURG THALM/SH SH from $18.00 to $14.00. They now have a "buy" rating on the stock.
4/3
03:22 am
acrv
What To Buy After You Sell The Russell 2000 [Seeking Alpha]
Low
Report
What To Buy After You Sell The Russell 2000 [Seeking Alpha]
4/1
01:04 pm
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $18.00 price target on the stock.
Medium
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $18.00 price target on the stock.
4/1
10:15 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $14.00 price target on the stock.
Low
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $14.00 price target on the stock.
3/29
08:16 am
acrv
Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
Low
Report
Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
3/28
08:09 am
acrv
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights [Yahoo! Finance]
High
Report
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights [Yahoo! Finance]
3/28
08:00 am
acrv
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
High
Report
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
3/5
04:43 pm
acrv
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316 [Yahoo! Finance]
Medium
Report
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316 [Yahoo! Finance]
3/5
04:30 pm
acrv
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
Medium
Report
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
3/4
08:00 am
acrv
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
High
Report
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
3/1
07:34 am
acrv
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $14.00 price target on the stock.
High
Report
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $14.00 price target on the stock.
2/27
08:00 am
acrv
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
High
Report
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
2/8
08:00 am
acrv
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovcevic-Liebisch, Ph.D., J.D., to Board of Directors
Medium
Report
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovcevic-Liebisch, Ph.D., J.D., to Board of Directors
2/6
08:00 am
acrv
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Low
Report
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference